跳至主要内容
临床试验/ITMCTR2100004821
ITMCTR2100004821招募中4 期

Efficacy and safety of Wuling capsule in the treatment of early Parkinson's disease with mild depression: a multicenter, randomized, double-blind, placebo-controlled study

Xinhua Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
45 至 80(—)
性别
All

入选标准

  • 1.Patients aged 45 to 80 years with primary Parkinson's disease, regardless of gender;
  • 2.Hoehn-Yahr grading < 3 at the onstage;
  • 3.MMSE >= 24 points;
  • 4.Accompanied with depressive symptoms (8 <= HAMD17 < 18);
  • 5.Stable basic treatment for Parkinson's disease;
  • 6.Sign informed consent.

排除标准

  • 1.Other nervous system diseases, mental diseases and serious physical diseases;
  • 2.History of alcohol and drug dependence;
  • 3.Dementia patients;
  • 4.High risk of suicide or suicide attempt within 6 months (HAMD-17 item 3 >= 3 points);
  • 5.Antidepressant treatment or other psychotic treatment in the past month;
  • 7.Those who participated in other clinical trials in recent 3 months;
  • 8.Pregnant or lactating women;
  • 9.Patients considered unsuitable for the study.

研究者

相似试验